A Randomized Clinical Trial of Triazolam in 3- to 5-year-olds

Abstract

Triazolam has shown promise as a sedative agent for use in pediatric dentistry. However, the efficacy of triazolam has not been previously examined in a placebo-controlled study. The present clinical trial used a two-group, randomized, double-blind study design to compare the efficacy of oral triazolam with that of a placebo. The primary hypothesis tested was that triazolam would reduce negative behaviors of pediatric dental patients compared with a placebo. A secondary hypothesis was that triazolam would increase the efficiency of dental treatment by reducing the need for time-consuming behavior management by the pediatric dentist. The subjects were 54 3- to 5-year-old children, randomly assigned to the drug and placebo groups. The active drug, 0.03 mg/kg triazolam (Halcion®), or lactose placebo was given orally 30 min before dental treatment. Behavior management techniques commonly used in pediatric dentistry were used during dental treatment. A single pediatric dentist provided all of the dental treatment. The procedure included an inferior block anesthesia and careful attention to anesthesia effectiveness. All sessions were video-taped and the tapes coded for child and dentist behaviors by an independent observer. There were no statistically significant differences between the groups with respect to completion of dental treatment. There were no significant differences found in either the total time or the percent of time that the subjects exhibited disruptive movements, verbal or non-verbal distress. The total use of time in the dental chair was slightly higher in the placebo than in the drug group due to more time spent preparing the child. Contrary to preliminary reports in the literature, this investigation found little or no improvement in child behavior when triazolam was used as a sedative compared with a placebo. However, triazolam did shorten the length of dental treatment, primarily by reducing dentist time in preparing the child for the dental procedure (e.g., establishing rapport and shaping behavior).

Keywords

sedation behavior pediatric dentistry triazolam

Get full access to this article

View all access options for this article.

References

American Academy of Pediatric Dentistry (1997 ). Guidelines for the elective use of pharmacologic sedation and deep sedation in pediatric dental patients. Pediatr Dent 19:48-52.

Coldwell SE , Milgrom P. , Getz T. , Ramsay DS (1997). Amnestic and anxiolytic effects of alprazolam in oral surgery patients. J Oral Maxillofac Surg 55:1061-1070.

Coldwell SE , Awamura K. , Milgrom P. , Depner KS , Kaufman E. , Preston KL , et al. (1999). Side effects of triazolam in children. Pediatr Dent 21:18-25.

Creedon RL (1994). Pharmacologic management of patient behavior. In: Dentistry for the child and adolescent. 6th ed. McDonald RE , Avery DR , editors. St. Louis: Mosby, pp. 307-334.

Cuthbert MI , Melamed BG (1982). A screening device: children at risk for dental fears and management problems. J Dent Child 49:432-436.

File SE , Easton P. , Skelly AM (1991). Amnesia for dental procedures and mood change following treatment with nitrous oxide or midazolam. Int Clin Psychopharmacol 6:169-178.

Flaitz CM , Nowak AJ , Hicks MJ (1986). Evaluation of the anterograde amnesic effect of rectally administered diazepam in the sedated pedodontic patient. J Dent Child 53:17-20.

Frankl SN , Shiere FR , Fogels HR (1962). Should the parent remain with the child in the dental operatory? J Dent Child 29:150-163.

Glick TH (1993). Neurologic skills: examination and diagnosis. Boston: Blackwell Scientific Publications .

10.

Gupta SK , Ellinwood EH , Nikaido AM , Heatherly DG (1990). Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. II Triazolam Pharmaceut Res 7:570-576.

11.

Henderson BN , Triplett G. , Gage TW ( 1994). Anxiolytic therapy: oral and intravenous sedation . Dent Clin North Am 38 :603-617.

12.

Karl HW , Milgrom P. , Domoto P. , Kharasch ED , Coldwell SE , Weinstein P. , et al. (1997). Pharmacokinetics of oral triazolam in children . J Clin Psychopharmacol 17:169-172.

13.

Kleinknecht RA , Bernstein DA (1978). The assessment of dental fear. Behav Ther 9:626-634.

14.

Loeffler PM (1992). Oral benzodiazepines and conscious sedation : a review. J Oral Maxillofac Surg 50:989-997.

15.

Meyer ML , Mourino AP , Farrington FH (1990). Comparison of triazolam to a chloral hydrate/hydroxyzine combination in the sedation of pediatric dental patients. Pediatr Dent 12:283-287.

16.

Milgrom P. , Weinstein P. (1999). Early childhood caries. A team approach to prevention and treatment. Seattle, WA: University of Washington, Continuing Dental Education.

17.

Milgrom P. , Weinstein P. , Getz T. ( 1995). Treating fearful dental patients. A patient management handbook. 2nd ed. Seattle, WA : University of Washington, Continuing Dental Education .

18.

Pakes GE , Brogden RN , Heel RC , Speight TM , Avery GS (1981). Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia. Drugs 22 :81-110.

19.

Quarnstrom FC , Milgrom P. , Moore PA (1992). Experience with triazolam in preschool children . Anesth Pain Control Dent 1:157-159.